TY  - JOUR

T1  - Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1

JO  - American Journal of Clinical Dermatology

UR  - http://dx.doi.org/10.1007/s40257-023-00817-0

PY  - 2023/10/07

AU  - Simpson EL

AU  - Blauvelt A

AU  - Silverberg JI

AU  - Cork MJ

AU  - Katoh N

AU  - Mark T

AU  - Schneider SKR

AU  - Wollenberg A

ED  - 

DO  - DOI: 10.1007/s40257-023-00817-0

PB  - Springer Science and Business Media LLC

Y2  - 2024/12/22

ER  -